Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

TELESTA THERAPEUTICS INC T.TST

"Telesta Therapeutics Inc is a biopharmaceutical company. The Company is engaged in the research, development, manufacturing and commercialization of human health products and technologies."


TSX:TST - Post by User

Comment by FarmaBoyon Sep 28, 2015 5:39am
141 Views
Post# 24140061

RE:RE:How many patients required...

RE:RE:How many patients required...Randomization of the patients at baseline (before study begins) should ensure that baseline characteristics between the two arms are similar and representative of the population as a whole. 

i.e. number of patients between 50 and 70 y.o should be similar, number of patients at CIS tumour stage should be similar, number of patients of certain ethnicities should be similar etc. between the two arms. 

Now of course randomization does not always ensure these variables are similar - especially in smaller sample sizes.

However, the baseline charadcteristics of the MCNA Ph III are public and are as we would expect - so while there is a theoretical possibility this process is not perfect, we know the facts in relation to this case. 
<< Previous
Bullboard Posts
Next >>